Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
$0.29
+4.0%
$0.27
$0.22
$3.67
$11.21M3.041.48 million shs206,460 shs
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
$8.00
-4.4%
$8.78
$5.00
$100.80
$11.51M0.85258,467 shs105,991 shs
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
$1.84
$2.24
$1.71
$20.28
$3.26M4.33162,657 shs25,107 shs
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.49
+2.8%
$1.17
$0.70
$2.44
$17.25M0.5155,443 shs9,982 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
+3.99%+7.05%+0.95%-34.62%-89.13%
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
-4.42%-12.85%+15.94%-45.21%-81.98%
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
0.00%-3.16%-23.65%-52.21%-99.36%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
+2.76%0.00%+29.57%+74.27%-30.37%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
2.102 of 5 stars
3.02.00.00.01.72.51.3
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
1.7899 of 5 stars
0.05.00.00.03.33.30.0
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
0.5741 of 5 stars
0.03.00.00.03.30.00.6
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
1.4484 of 5 stars
0.05.00.00.02.71.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
2.00
Hold$13.834,719.98% Upside
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
0.00
N/AN/AN/A
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
0.00
N/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
N/AN/AN/AN/A$3.42 per shareN/A
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
$1.45M7.97N/AN/A$0.37 per share21.62
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
$8.04M0.40$184.00 per share0.01$40.58 per share0.05
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.84M9.37N/AN/A$2.77 per share0.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
-$117.67M-$2.07N/AN/AN/AN/A-115.62%-88.94%7/30/2025 (Estimated)
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
-$24.99M-$23.25N/AN/A-1,067.82%-2,516.84%-132.95%N/A
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
$23.92MN/A0.00N/AN/AN/AN/A6/14/2025 (Estimated)
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
-$10.28MN/A0.00N/A-207.77%-14.08%-9.61%8/11/2025 (Estimated)

Latest RDHL, TXMD, HCWB, and ATHA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
N/A-$0.05N/A-$0.05N/AN/A
5/13/2025Q1 2025
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/A-$0.06N/A-$0.06N/A$0.39 million
5/9/2025Q1 2025
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
-$0.20-$0.23-$0.03-$0.23N/AN/A
3/28/2025Q4 2024
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
N/A-$3.20N/A-$0.08N/A$0.40 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
N/AN/AN/AN/AN/A
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
N/AN/AN/AN/AN/A
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
N/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
N/A
2.95
2.95
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
N/A
0.07
0.07
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
N/A
0.74
0.56
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/A
2.03
2.03

Institutional Ownership

CompanyInstitutional Ownership
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
57.12%
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
2.96%
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
7.20%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
30.74%

Insider Ownership

CompanyInsider Ownership
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
22.10%
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
49.90%
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
6.81%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
2.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
4039.04 million31.01 millionOptionable
HCW Biologics Inc. stock logo
HCWB
HCW Biologics
401.44 million22.32 millionNot Optionable
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
2101.77 million1.19 millionNo Data
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
42011.57 million11.27 millionOptionable

Recent News About These Companies

TherapeuticsMD Shifts Focus with Lower Q3 Losses
TherapeuticsMD Reports Reduced Losses Amid Strategic Shift
TherapeuticsMD (NASDAQ:TXMD) Stock, Option Chain

New MarketBeat Followers Over Time

Media Sentiment Over Time

Athira Pharma stock logo

Athira Pharma NASDAQ:ATHA

$0.29 +0.01 (+3.99%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.29 0.00 (0.00%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

HCW Biologics stock logo

HCW Biologics NASDAQ:HCWB

$8.00 -0.37 (-4.42%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$7.85 -0.15 (-1.88%)
As of 08:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

RedHill Biopharma stock logo

RedHill Biopharma NASDAQ:RDHL

$1.84 0.00 (0.00%)
Closing price 05/27/2025 03:59 PM Eastern
Extended Trading
$1.78 -0.07 (-3.53%)
As of 06:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

TherapeuticsMD stock logo

TherapeuticsMD NASDAQ:TXMD

$1.49 +0.04 (+2.76%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.46 -0.03 (-2.35%)
As of 07:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.